Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference
Rhea-AI Summary
Arcutis Biotherapeutics (Nasdaq: ARQT) will report its fourth quarter and full year 2025 financial results and provide a business update on Wednesday, February 25, 2026 after U.S. market close. The company will host a conference call and webcast the same day at 4:30 p.m. ET, with presentation materials available in the company Events section and an archived replay posted afterward.
Arcutis management will also present at the Guggenheim Emerging Outlook: Biotech Summit on Wednesday, February 11, 2026 with a fireside chat at 11:30 a.m. ET; that webcast and a replay will be accessible via the company Events page for 180 days.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ARQT declined 1.69%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ARQT gained 3.21% with modestly higher volume, while close biotech peers like APGE, TARS, AGIO, IRON, and TVTX were also up 0.49–2.60%. However, the momentum scanner only flagged DNLI (+12.5%) and did not show a coordinated move across multiple peers, suggesting a more stock-specific reaction.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 12 | Strategic priorities update | Positive | -5.1% | Outlined 2026 sales guidance, pipeline milestones, and cash flow transition. |
| Dec 08 | Board/leadership change | Positive | -4.1% | Added experienced director and honored retiring founder with advisory role. |
| Nov 17 | Regulatory filing update | Positive | +4.7% | FDA accepted sNDA for ZORYVE 0.3% in children ages 2–5. |
| Nov 13 | Clinical trial milestone | Positive | -2.5% | Completed enrollment in INTEGUMENT-INFANT Phase 2 atopic dermatitis study. |
| Nov 07 | Equity compensation grants | Positive | -2.0% | Reported inducement RSU grants to several new employees. |
Recent history shows mostly positive operational or strategic news often followed by flat-to-negative price reactions, with only one clear alignment on favorable regulatory news.
Over the last few months, Arcutis has reported several positive corporate and pipeline developments. In November 2025, the company completed enrollment in the INTEGUMENT-INFANT Phase 2 study and had an FDA acceptance of a supplemental NDA for ZORYVE cream 0.3% with a June 29, 2026 PDUFA date. Board and leadership changes, inducement grants, and a January 12, 2026 update on 2026 strategic priorities all highlighted growth initiatives, yet price reactions were often negative or muted.
Market Pulse Summary
This announcement sets the timetable for Arcutis’ fourth quarter and full year 2025 financial results and highlights added visibility through a Guggenheim biotech summit appearance. In recent months, the company reported positive regulatory and clinical milestones alongside strategic updates, yet share reactions were often mixed. Investors may watch the upcoming call for detail on ZORYVE’s commercial performance, cash flow trends, and progress against previously outlined 2026 development milestones.
AI-generated analysis. Not financial advice.
- Fourth quarter and full year 2025 investor conference call scheduled for February 25, 2026 at 4:30 p.m. ET
- Arcutis management to present at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026
WESTLAKE VILLAGE, Calif., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its fourth quarter and full year 2025 financial results and provide a business update on Wednesday, February 25, 2026 after the U.S. financial markets close. The Company will also host a conference call and webcast the same day at 4:30 p.m. ET.
A live webcast of the call and related presentation materials will be available on the “Events” section of the Company’s website. An archived replay of the webcast will be available on the Arcutis investor website following the conference call.
Arcutis also announced it will participate in the following investor conference:
Guggenheim Emerging Outlook: Biotech Summit
Fireside Chat: Wednesday, February 11, 2026 at 11:30 a.m. ET
The webcast for this conference may be accessed via the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis website for 180 days following the conference.
About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on The Company’s current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2025, as well as any subsequent filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available.
Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com
Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com
FAQ
When will Arcutis (ARQT) report Q4 and full year 2025 results?
What time is the Arcutis (ARQT) earnings call on February 25, 2026?
How can investors access the Arcutis (ARQT) webcast and presentation materials?
When will Arcutis management present at the Guggenheim Biotech Summit?
Will there be a replay of the Arcutis (ARQT) investor presentations?
